SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli¹, Daniel Mrak¹, Thomas Perkmann², Helmuth Haslacher², Daniel Aletaha³

Affiliations

¹ Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
² Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
³ Division of Rheumatology, Medical University of Vienna, Vienna, Austria daniel.aletaha@meduniwien.ac.at.

PMID: 33958323
DOI: 10.1136/annrheumdis-2021-220408

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al. Ann Rheum Dis. 2021 Oct.

. 2021 Oct;80(10):1355-1356.

doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.

Authors

Michael Markus Bonelli¹, Daniel Mrak¹, Thomas Perkmann², Helmuth Haslacher², Daniel Aletaha³

Affiliations

¹ Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
² Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
³ Division of Rheumatology, Medical University of Vienna, Vienna, Austria daniel.aletaha@meduniwien.ac.at.

PMID: 33958323
DOI: 10.1136/annrheumdis-2021-220408

No abstract available

Keywords: B-lymphocytes; COVID-19; rituximab.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.
Connolly CM, Koenig D, Ravi SN, Azar A, Kant S, Dalal M, Duchen J, Seo P, Antiochos B, Paik JJ, Geetha D. Connolly CM, et al. Ann Rheum Dis. 2021 Oct;80(10):e164. doi: 10.1136/annrheumdis-2021-220972. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340978 No abstract available.
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli et al.
Benucci M, Damiani A, Infantino M, Manfredi M, Grossi V, Lari B, Li Gobbi F, Sarzi Puttini P. Benucci M, et al. Ann Rheum Dis. 2021 Oct;80(10):e166. doi: 10.1136/annrheumdis-2021-220829. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340979 No abstract available.
Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.
Chung SH, Wener M, Bays AM, Rahbar H, Morishima C, Bryan AB, Fink SL, Cohen S, Mani NS, Chaudhary A, Gardner GC. Chung SH, et al. Ann Rheum Dis. 2021 Oct;80(10):e165. doi: 10.1136/annrheumdis-2021-220957. Epub 2021 Aug 2. Ann Rheum Dis. 2021. PMID: 34340981 No abstract available.

Cited by

Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution.
Furlan A, Rossi MC, Gherlinzoni F, Scotton P. Furlan A, et al. Hematol Rep. 2022 Apr 13;14(2):135-142. doi: 10.3390/hematolrep14020020. Hematol Rep. 2022. PMID: 35466184 Free PMC article.
SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.
Aryanian Z, Balighi K, Hatami P, Goodarzi A, Mohandesi NA, Afshar ZM. Aryanian Z, et al. Dermatol Ther. 2022 May;35(5):e15430. doi: 10.1111/dth.15430. Epub 2022 Mar 22. Dermatol Ther. 2022. PMID: 35261123 Free PMC article. Review.
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK, Van Keulen VP, Erskine CL, Shah M, Hummel A, Stachowitz M, Fatis S, Granger D, Block MS, Duarte-García A, Warrington KJ, Theel ES, Zhou X, Zeng H, Specks U, Escalante P, Peikert T. Marty PK, et al. Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981. eCollection 2022. Front Immunol. 2022. PMID: 35154159 Free PMC article.
The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
Duni A, Markopoulos GS, Mallioras I, Pappas H, Pappas E, Koutlas V, Tzalavra E, Baxevanos G, Priska S, Gartzonika K, Mitsis M, Dounousi E. Duni A, et al. Front Immunol. 2021 Dec 3;12:760249. doi: 10.3389/fimmu.2021.760249. eCollection 2021. Front Immunol. 2021. PMID: 34925330 Free PMC article.
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Koyama T, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Funakoshi Y, et al. Vaccines (Basel). 2022 Jun 17;10(6):965. doi: 10.3390/vaccines10060965. Vaccines (Basel). 2022. PMID: 35746573 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Affiliations

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Authors

Affiliations

Conflict of interest statement

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous